ArticleOncology letters2026
Adjuvant immunotherapy plus chemotherapy and maintenance immunotherapy for pulmonary lymphoepithelioma-like carcinoma with hepatitis B virus infection, KRAS mutation and high expression of programmed death ligand 1: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of non-small cell lung cancer, often associated with Epstein-Barr virus (EBV) infection. It typically exhibits distinct epidemiological and molecular features compared to other lung malignancies. However, the clinical behavior and optimal therapeutic strategies for PLELC, particularly in the presence of concomitant viral infections or specific genetic mutations, remain poorly defined. This report comprehensively outlines the treatment process of a 58-year-old female patient diagnosed with PLELC in the right middle lobe of the lung. Following surgical resection, the diagnosis was confirmed as PLELC, which was found to be associated with hepatitis B virus (HBV) infection, KRAS mutation and high expression of programmed death ligand 1 (PD-L1). The patient subsequently received adjuvant treatment with immunotherapy (penpulimab) combined with chemotherapy, followed by penpulimab maintenance therapy, resulting in a progression-free survival of >44 months. At present, the patient is still alive and healthy, and can undergo regular follow-ups and re-examinations. Notably, preoperative testing showed a positive EBV status, which became negative post-surgery. This case highlights several key aspects. First, it examines the diagnostic and therapeutic characteristics of PLELC with a positive EBV test result before surgery that turned negative after surgical resection. Second, it assesses the influence of high PD-L1 expression and concurrent HBV infection on the efficacy and safety of immunotherapy. Third, it explores the clinical implications of the KRAS mutation in this unique tumor subtype. The overarching goal of this exploration is to offer valuable clinical guidance for managing this rare and understudied subtype of lung cancer, particularly in the context of multimodal therapy involving immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.